Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Tardive dyskinesia: No clinically important improvement · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether DOPAMINERGIC DRUGS changes tardive dyskinesia: No clinically important improvement compared with OTHER DRUGS (very low certainty).
1 finding from 1 review
Tardive dyskinesia: Deterioration of symptoms · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether NORADRENERGIC DRUGS changes tardive dyskinesia: deterioration compared with PLACEBO (very low certainty).
1 finding from 1 review
Tardive dyskinesia: Deterioration of symptoms · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether DOPAMINERGIC DRUGS changes tardive dyskinesia: Deterioration compared with OTHER DRUGS (very low certainty).
1 finding from 1 review
Adverse events ‐ not reported · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Mental state ‐ not reported · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Secondary outcome: acceptability of treatment · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether DOPAMINERGIC DRUGS changes acceptability of treatment: Leaving the study early compared with OTHER DRUGS (very low certainty).
1 finding from 1 review
Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Adverse events ‐ not reported · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Mental state ‐ not reported · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Secondary outcome: acceptability of treatment · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether NORADRENERGIC DRUGS changes acceptability of treatment: Leaving the study early compared with PLACEBO (very low certainty).
1 finding from 1 review
No improvement in quality of life · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether NORADRENERGIC DRUGS changes no improvement in quality of life compared with PLACEBO (very low certainty).
1 finding from 1 review
Tardive dyskinesia: No clinically important improvement · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether NORADRENERGIC DRUGS changes tardive dyskinesia: No clinically important improvement compared with DOPAMINERGIC DRUGS (very low certainty).
1 finding from 1 review
Tardive dyskinesia: Deterioration of symptoms · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Adverse events ‐ not reported · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Tardive dyskinesia: No clinically important improvement · female and male 42 (mean) years old patients with schizophrenia or schizoaffective disorder and antipsychotic‐induced tardive dyskinesia
It is very uncertain whether reduced dose of antipsychotics changes tardive dyskinesia: no clinically important improvement compared with antipsychotic maintenance (very low certainty).
1 finding from 1 review
Mental state · psychiatric patients (schizophrenia) with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Adverse effect: any ‐ not reported · psychiatric patients (schizophrenia) with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Adverse effects: use of antiparkinsonism drugs · psychiatric patients (schizophrenia) with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether switch to another antipsychotic changes adverse effects: use of antiparkinsonism drugs compared with antipsychotic cessation (very low certainty).
1 finding from 1 review
Leaving the study early · psychiatric patients (schizophrenia) with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether switch to another antipsychotic changes acceptability of the treatment: leaving the study early compared with antipsychotic cessation (very low certainty).
1 finding from 1 review